29874-01-9

Usage

Uses

3-Chlorobenzylmagnesium chloride is used as pharmaceutical intermediate.

InChI:InChI=1/C7H6Cl.ClH.Mg/c1-6-3-2-4-7(8)5-6;;/h2-5H,1H2;1H;/q;;+1/p-1/rC7H6Cl2Mg/c8-7-3-1-2-6(4-7)5-10-9/h1-4H,5H2

Downstream Products

• 1385021-00-0 2-(3-chlorophenyl)-1-(1-triisopropylsilanyl-1H-pyrrolo[2,3-b]pyridin-3-yl)ethanone 
• 27640-06-8 (CH₃)3SnCH₂C₆H₄-m-Cl 
• 37658-75-6 (ClC₆H₄CH₂)4Zr 
• 431988-91-9 5-[4-(3-chloro-phenyl)-3-oxo-butyl]-pyrrolidin-2-one 
• 89122-78-1 C₁₈H₁₈BrClO 
• 89122-64-5 (E)-2-(3-chlorostyryl)phenol 
• 926933-74-6 4-[4-(3-chlorobenzyl)-4-methoxy-piperidin-1-yl]-benzoic acid ethyl ester 
• 891833-64-0 2,2-dimethyl-propionic acid 2-[4-(3-chloro-benzyl)-2-oxo-3,4-dihydro-2H-pyridin-1-yl]-4,5-bis-(2,2-dimethyl-propionyloxy)-6-(2,2-dimethyl-propionyloxymethyl)-tetrahydro-pyran-3-yl ester 
• 926933-62-2 4-[4-(3-chlorobenzyl)-4-hydroxy-piperidin-1-yl]-benzoic acid ethyl ester 
• 89122-91-8 2-[2-(3-Chloro-phenyl)-1-hydroxy-ethyl]-phenol 

Relevant academic research and scientific papers

PROCESS FOR THE PREPARATION OF GRIGNARD COMPOUNDS

The invention relates to a process for the preparation of Grignard compounds using a continuous method which involves the reaction of an organic halide dissolved in an organic solvent with metallic magnesium which, together with the activator solution in an organic solvent, fills the flow reactor or optionally a system of flow reactors, and subsequently, the resulting reaction mixture is fed into the terminal flow reactor containing metallic magnesium in order to achieve complete conversion of the organic halide, whereby preferably the organic solvent is re-circulated to flow reactors in a form of vapour.